Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 8/20 | 0.52 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.47 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5758023 | 0.82 | HTR2A (0.61) | CCR5KCNA3HTR2A | |
| SCHEMBL5634565 | 0.82 | EGFR (0.48) | CCR5KCNA3 | |
| SCHEMBL27474479 | 0.82 | TP53 (0.50) | CCR5KCNA3 | |
| SCHEMBL14514117 | 0.82 | EGFR (0.48) | CCR5KCNA3 | |
| Hydrochloric Acid SCHEMBL6008822 | 0.81 | HTR2A (0.60) | CCR5KCNA3HTR2A | |
| SCHEMBL6657922 | 0.80 | ABL1 (0.68) | S1PR5ABL1RIN1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL9166082 | 0.78 | ABL1 (0.66) | S1PR5ABL1RIN1SIGMAR1 | |
| SCHEMBL5756545 | 0.78 | CARM1 (0.64) | SIGMAR1 | |
| SCHEMBL5760363 | 0.77 | HTR2A (0.61) | HTR2A | |
| SCHEMBL14514069 | 0.77 | KCNA3 (0.44) | CCR5KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078537-B2 | Phenylalkyl diamine and amide analogs | SK CORPORATION (KR) | 2006-07-18 | — | — | US | claimed |
| US-7078537-B2 | Phenylalkyl diamine and amide analogs | SK CORPORATION (KR) | 2006-07-18 | — | — | US | disclosed |
| US-20030105079-A1 | Novel phenylalkyl diamine and amide analogs | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105079-A1 | Novel phenylalkyl diamine and amide analogs | SIGMAR1, TAAR1, OPRL1 | CCR5 796/4885KCNA3 785/4885S1PR5 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.